In March 2025, the company declared new programs for a immediate-to-client supplying of its Wegovy weight loss drug. The company recognized a fresh pharmacy, referred to as NovoCare, which would demand prospects $499 per month for use of the drug, fewer than fifty percent the price of the drug as a result of other pharmaceutical distribution networ